Skip to main content

ONIVYDE irinotecan (as sucrosofate) 43 mg/10 mL nanoliposomal concentrated injection for infusion, Ervier Laboratories (Aust) Pty Ltd, CON-1248

Product name
ONIVYDE irinotecan (as sucrosofate) 43 mg/10 mL nanoliposomal concentrated injection for infusion
Sponsor name
Ervier Laboratories (Aust) Pty Ltd
Batches
Lot 001231, Lot 001825 and Lot 004892
Consent start
Consent no.
CON-1248
Standard
Paragraph 8(1)(l) of Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines
Non-compliance with standard
The product does not have the instructions for preparation, storage conditions or the maximum storage period on the label or as a package insert.
Conditions imposed
A 'Dear Healthcare Provider' letter identical to that provided to the TGA on 14 June 2024 will be supplied with each affected batch providing details of the missing information and weblinks to where it can be found.
Therapeutic product type
Prescription medicines

Help us improve the Therapeutic Goods Administration site